Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Theodore Pincus

Showing results (101-110 of 202) with videos related to

Pageof 21
Sort By:
The Journal of Rheumatology|October 16, 2021
Should Quantitative Measures and Management of Rheumatoid Arthritis Include More Than Control of Inflammatory Activity?Theodore Pincus, Martin J Bergman, Yusuf Yazici
Bulletin of the NYU Hospital for Joint Diseases|October 26, 2010
Beyond RAPID3 - practical use of the MDHAQ to improve doctor-patient communicationTheodore Pincus, Yusuf Yazici, Martin J Bergman
The Journal of Rheumatology|August 13, 2009
Quantitative clinical rheumatology: why is a test for anti-CCP antibodies included in most routine care for rheumatoid arthritis while a HAQ/MDHAQ remains largely a research tool?Theodore Pincus, Yusuf Yazici, Martin J Bergman
Bulletin of the Hospital for Joint Disease (2013)|November 14, 2013
Efficacy and safety of methotrexate in combination with other non-biologic disease-modifying antirheumatic drugs (DMARDs) in treatment of rheumatoid arthritisIsabel Castrejón, Kathryn A Gibson, Theodore Pincus
Arthritis and Rheumatism|April 16, 2002
Urgent care and tight control of rheumatoid arthritis as in diabetes and hypertension: better treatments but a shortage of rheumatologistsTheodore Pincus, Allan Gibofsky, Michael E Weinblatt
Rheumatic Diseases Clinics of North America|December 8, 2009
Patient questionnaires in rheumatoid arthritis: advantages and limitations as a quantitative, standardized scientific medical historyTheodore Pincus, Yusuf Yazici, Martin J Bergman
Rheumatic Diseases Clinics of North America|December 8, 2009
RAPID3, an index to assess and monitor patients with rheumatoid arthritis, without formal joint counts: similar results to DAS28 and CDAI in clinical trials and clinical careTheodore Pincus, Yusuf Yazici, Martin J Bergman
Rheumatic Diseases Clinics of North America|December 8, 2009
A Standard Protocol to Evaluate Rheumatoid Arthritis (SPERA) for efficient capture of essential data from a patient and a health professional in a uniform "scientific" formatTheodore Pincus, Leigh F Callahan, Tuulikki Sokka
Rheumatic Diseases Clinics of North America|December 8, 2009
Quality control of a medical history: improving accuracy with patient participation, supported by a four-page version of the multidimensional health assessment questionnaire (MDHAQ)Theodore Pincus, Yusuf Yazici, Christopher J Swearingen
Arthritis Care & Research|December 4, 2012
Decline of mean initial prednisone dosage from 10.3 to 3.6 mg/day to treat rheumatoid arthritis between 1980 and 2004 in one clinical setting, with long-term effectiveness of dosages less than 5 mg/dayTheodore Pincus, Tuulikki Sokka, Isabel Castrejón, et al.
Pageof 21

Showing results (101-110 of 202) with videos related to

Sort By:
Pageof 21
The Journal of Rheumatology|October 16, 2021
Should Quantitative Measures and Management of Rheumatoid Arthritis Include More Than Control of Inflammatory Activity?Theodore Pincus, Martin J Bergman, Yusuf Yazici
Bulletin of the NYU Hospital for Joint Diseases|October 26, 2010
Beyond RAPID3 - practical use of the MDHAQ to improve doctor-patient communicationTheodore Pincus, Yusuf Yazici, Martin J Bergman
The Journal of Rheumatology|August 13, 2009
Quantitative clinical rheumatology: why is a test for anti-CCP antibodies included in most routine care for rheumatoid arthritis while a HAQ/MDHAQ remains largely a research tool?Theodore Pincus, Yusuf Yazici, Martin J Bergman
Bulletin of the Hospital for Joint Disease (2013)|November 14, 2013
Efficacy and safety of methotrexate in combination with other non-biologic disease-modifying antirheumatic drugs (DMARDs) in treatment of rheumatoid arthritisIsabel Castrejón, Kathryn A Gibson, Theodore Pincus
Arthritis and Rheumatism|April 16, 2002
Urgent care and tight control of rheumatoid arthritis as in diabetes and hypertension: better treatments but a shortage of rheumatologistsTheodore Pincus, Allan Gibofsky, Michael E Weinblatt
Rheumatic Diseases Clinics of North America|December 8, 2009
Patient questionnaires in rheumatoid arthritis: advantages and limitations as a quantitative, standardized scientific medical historyTheodore Pincus, Yusuf Yazici, Martin J Bergman
Rheumatic Diseases Clinics of North America|December 8, 2009
RAPID3, an index to assess and monitor patients with rheumatoid arthritis, without formal joint counts: similar results to DAS28 and CDAI in clinical trials and clinical careTheodore Pincus, Yusuf Yazici, Martin J Bergman
Rheumatic Diseases Clinics of North America|December 8, 2009
A Standard Protocol to Evaluate Rheumatoid Arthritis (SPERA) for efficient capture of essential data from a patient and a health professional in a uniform "scientific" formatTheodore Pincus, Leigh F Callahan, Tuulikki Sokka
Rheumatic Diseases Clinics of North America|December 8, 2009
Quality control of a medical history: improving accuracy with patient participation, supported by a four-page version of the multidimensional health assessment questionnaire (MDHAQ)Theodore Pincus, Yusuf Yazici, Christopher J Swearingen
Arthritis Care & Research|December 4, 2012
Decline of mean initial prednisone dosage from 10.3 to 3.6 mg/day to treat rheumatoid arthritis between 1980 and 2004 in one clinical setting, with long-term effectiveness of dosages less than 5 mg/dayTheodore Pincus, Tuulikki Sokka, Isabel Castrejón, et al.
Pageof 21